Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Phase 1/2 study of safety/efficacy using trabectedin, ipilimumab, and nivolumab as first-line treatment of advanced soft tissue sarcoma (STS).
Authors
Erlinda Maria Gordon
Sarcoma Oncology Center, Santa Monica, CA
Erlinda Maria Gordon, Victoria S. Chua-Alcala, Katherine Kim, William W. Tseng, Doris M Quon, Sant P Chawla
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses
Sub Track
Special Populations
Clinical Trial Registration Number
NCT 03138161
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr TPS46)
DOI
10.1200/JCO.2018.36.5_suppl.TPS46
Abstract #
TPS46
Poster Bd #
M10
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
Phase 1/2 study of safety/efficacy using trabectedin, ipilimumab and nivolumab triple therapy as first line treatment of advanced soft tissue sarcoma.
First Author: Erlinda Maria Gordon
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
The SAINT: Initial results of a phase I/II study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.
First Author: Sant P. Chawla
Poster
2019 ASCO Annual Meeting
SAINT: Results of a phase 1/2 study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.
First Author: Erlinda Maria Gordon
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
First Author: Kohei Shitara